Find out more ways to treat psoriasis in the future

Published Date: 02 Mar 2023

According to MBA MD Andrew Blauvelt, the development of oral biologics and early treatment to replace the disease is a possibility.

Read Full News

Latest News

Research Uncovers Mental Health Toll of Alopecia on Women

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

ICI-Related Toxicity Diagnoses Differ for Dark vs Light Skin

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

Consensus Defines Vitiligo Severity, Relapse Beyond BSA

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

First-Line Biologics May Improve Psoriasis Outcomes

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer-Valneva Lyme Vaccine Shows More Than 70% Efficacy but Misses Key Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

Can Mpox Vaccine Immunity Last for 5 Years?

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Todays Updates

Insulin Resistance Detected Early May Guide HS Therapy

Screening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.

Dermatomyositis: Targeted Drug Shows Promise vs Placebo

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Melasma: A New Era of Topical Treatment Options Galore

Combination therapies remain key as multiple agents for melasma hit the market.

LAAC an Alternative for NOAC in Lower-Risk AF Patients

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Fibrinolytic Beats Current Standard for Intermediate-Risk PE

For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.

PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

High Dx Yield Supports Workup for INOCA

Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.

Latest News

Black women are at greater risk for depression and anxiety, and scarring forms are linked to more disorders.

A review of published studies suggests that skin toxicities related to checkpoint inhibitors may be managed differently in patients with skin of color vs lighter skin tones.

An international consensus study establishes standardized definitions for vitiligo severity and relapse, emphasizing that body surface area alone is insufficient to capture disease burden.

Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, ⁠even as it missed its main goal.

The modified vaccinia Ankara-Bavarian Nordic vaccine induces sustained immune memory for up to 5 years, and a single booster dose at 5 years sharply raises antibody levels, a prospective study shows.

News All Time

HSV-1 May Be Increasing in Infants

A new study suggests that HSV-1 has become the dominant subtype among newborns.

Secukinumab Gets FDA Nod for Adolescent HS

Weight-based injectable’s approval is based in part on other pediatric indications.

Low-Beta Radiation Patch Offers Alternative NMSC Treatment

Similar to brachytherapy, OncoPatch could be an option for patients who have superficial lesions or who aren’t surgical candidates.

UK Approves New JAK Inhibitor for Severe Alopecia

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on NHS access.

What Does FDA Food Pyramid Mean for Cancer Risk and Care?

Much of the new FDA food guidance aligns with existing advice, but some areas may introduce confusion to advising patients on diet and cancer prevention and survival.

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis

Full results from the pivotal trials submitted to support approval have not yet been reported.

Early Intensive Therapy Best for PsA With Poor Prognosis

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes were maintained at 48 weeks in the TNFi group.

Guselkumab Effective After TNF Inhibitor Failure in PsA

Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.

Meta-analysis: Dermoscopic Features Distinguish ALM

Parallel ridge and multicomponent patterns are the most common dermoscopic features that identify acral lentiginous melanoma, according to a meta-analysis.

Geriatric Oncology Has Become Personalized: Here’s Why

As immunotherapy reshaped cancer care, geriatric oncology shifted toward personalized, geriatric assessment-guided treatment that prioritizes function, safety, and what matters most to older adults.

Hidradenitis Suppurativa Raises Risk for Self-Harm, Suicide

Patients with hidradenitis suppurativa have a higher risk for self-harm and suicide than matched control individuals, according to the results of a Danish cohort study.

Perianal Abscess Tied to Crohn's Disease Risk in Older Kids

Older children with perianal abscess or fistula-in-ano, especially those with recurrent perianal abscess or fistula-in-ano or gastrointestinal symptoms, are more likely to develop Crohn's disease.

Bimekizumab Not Tied to Mental Health Risk, Study Suggests

A study suggests that bimekizumab does not increase the risk for depression or suicidal ideation compared with IL-23 inhibitors in adults with psoriasis.

Should Biology Replace Organ Labels in Cancer Treatment?

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

PIP Matches PrEP for Low-Risk HIV

The use of medicine at home offers convenience and curbs costs.

Can Physical Activity Improve Skin Cancer Outcomes?

Physical activity is associated with a reduced risk for all-cause mortality and improved survival in patients with skin cancer, a meta-analysis shows.

Recommended News For You

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

Breast cancer-related fatigue: The benefits of adapted physical activity

After two years, a significant left nasal obstruction was finally diagnosed.

Is Laughter Good for Blood Glucose Control?

Review looks at potential treatment targets in the tumor microenvironment.

AMA President-Elect Confronts a New Challenge: A Brain Tumor

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries

Recommended Articles For You

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms 

Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment 

The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough 

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Results for Anorexia Nervosa with Psilocybin.

2.

Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple Myeloma

3.

Two medications might work better for breast cancers that are resistant to one.

4.

The most precise research tools for the deadliest blood cancer have been developed.

5.

Error on the MGUS-Autoimmune Disease Association.

1.

Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields

2.

Uncovering the Reality of Colon Cancer: A Look at Real Images

3.

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion

4.

Precision Oncology: Tailoring Cancer Treatment for the Individual

5.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot